RESUMO
Objectives of the investigations were to prepare RGD grafted docetaxel liposomes (RGD-PEG-LP-DC) using supercritical fluid technology and evaluate it in vitro for cytotoxicity, DNA content analysis, mechanism of cell death, and in vivo for pharmacokinetic and biodistribution studies in BALB/c mice. The RGD-PEG-LP-DCs were found to be most cytotoxic in BT-20 and MDA-MB-231 cell lines. The flowcytometry results shows at 48 hours, 96% G2 phase arrest for RGD-PEG-LP-DC at 5 nM drug concentration. The mode of cell death was found to be mainly by necrosis at low drug equivalent concentration (1 nM) and by apoptosis at high drug equivalent concentration (10 nM). With increase in time and concentration the mode of cell death by apoptosis was found to be increasing. Biodistribution demonstrated that site specific drug distribution, t(1/2), and MRT improved significantly for RGD-PEG-LP-DC. From the studies site specific and sustained intracellular drug delivery from RGD-PEG-LP-DCs may provide promising strategy in enhancing embattled against breast cancer treatment. FROM
Assuntos
Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Nanocápsulas/química , Oligopeptídeos/química , Polietilenoglicóis/química , Taxoides/administração & dosagem , Taxoides/farmacocinética , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacocinética , Apoptose/efeitos dos fármacos , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Docetaxel , Feminino , Lipossomos/administração & dosagem , Lipossomos/química , Taxa de Depuração Metabólica , Camundongos , Camundongos Endogâmicos BALB C , Nanocápsulas/administração & dosagem , Coelhos , Distribuição Tecidual , Resultado do TratamentoRESUMO
Carboxylated carbon nanotubes stand as the most promising nanovectors for biomedical and pharmaceutical applications due to their ease of covalent conjugation with eclectic functional molecules including therapeutic drugs, proteins, and oligonucleotides. In the present study, we attempt to investigate how the toxicity of acid-oxidized multiwalled carbon nanotubes (MWCNTs) can be tweaked by altering their degree of functionalization and correlate the toxicity trend with their biodistribution profile. In line with that rationale, mice were exposed to 10 mg/kg of pristine (p) and acid-oxidized (f) MWCNTs with varying degrees of carboxylation through a single dose of intravenous injection. Thereafter, extensive toxicity studies were carried out to comprehend the short-term (7 day) and long-term (28 day) impact of p- and various f-MWCNT preparations on the physiology of healthy mice. Pristine MWCNTs with a high aspect ratio, surface hydrophobicity, and metallic impurities were found to induce significant hepatotoxicity and oxidative damage in mice, albeit the damage was recovered after 28 days of treatment. Conversely, acid-oxidized carboxylated CNTs with shorter lengths, hydrophilic surfaces, and high aqueous dispersibility proved to be less toxic and more biocompatible than their pristine counterparts. A thorough scrutiny of various biochemical parameters, inflammation indexes, and histopathological examination of liver indicated that toxicity of MWCNTs systematically decreased with the increased functionalization density. The degree of shortening and functionalization achieved by refluxing p-MWCNTs with strong mineral acids for 4 h were sufficient to render the CNTs completely hydrophilic and biocompatible, while inducing minimal hepatic accumulation and inflammation. Quantitative biodistribution studies in mice, intravenously injected with Tc-99m labeled MWCNTs, clearly designated that clearance of CNTs from reticuloendothelial system (RES) organs such as liver, spleen, and lungs was critically functionalization density dependent. Well-individualized MWCNTs with shorter lengths (<500 nm) and higher degrees of oxidation (surface carboxyl density >3 µmol/mg) were not retained in any of the RES organs and rapidly cleared out from the systematic circulation through renal excretion route without inducing any obvious nephrotoxicity. As both p- and f-MWCNT-treated groups were devoid of any obvious nephrotoxicity, CNTs with larger dimensions and lower degrees of functionalization, which fail to clear out from the body via renal excretion route, were thought to be excreted via biliary pathway in faeces.
Assuntos
Materiais Biocompatíveis/toxicidade , Fulerenos/toxicidade , Nanotecnologia/métodos , Nanotubos de Carbono/toxicidade , Animais , Materiais Biocompatíveis/química , Materiais Biocompatíveis/farmacocinética , Fulerenos/química , Fulerenos/farmacocinética , Interações Hidrofóbicas e Hidrofílicas , Injeções Intravenosas , Rim/química , Fígado/química , Pulmão/química , Camundongos , Nanotubos de Carbono/química , Oxirredução , Baço/química , Tecnécio/análise , Distribuição TecidualRESUMO
The present investigation was aimed at developing PEGylated PLGA nanoparticles of cytarabine. PLGA Nanoparticles were prepared by modified nanoprecipitation method, optimized for mean particle size (152 ± 6 nm) and entrapment efficiency (41.1 ± 0.8%) by a 3² factorial design. The PEGylated PLGA nanoparticles of cytarabine had a zeta potential of -7.5 ± 1.3 mV and sustained the release of cytarabine for 48 h by Fickian diffusion. The IC50 values for L1210 cells were 6.5, 5.3, and 2.2 µM for cytarabine, cytarabine loaded PLGA nanoparticles and cytarabine loaded PLGA-mPEG nanoparticles respectively. Confocal microscopy and flow cytometry showed that the nanoparticles were internalized by the L1210 cells and not simply bound to their surface. Biodistribution studies showed that the PEGylated nanoparticles of cytarabine were present in significantly higher concentrations in blood circulation as well as in brain and bones and avoided RES uptake as compared to the free drug.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Citarabina/administração & dosagem , Preparações de Ação Retardada/química , Ácido Láctico/química , Nanopartículas/química , Polietilenoglicóis/química , Ácido Poliglicólico/química , Animais , Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/sangue , Antimetabólitos Antineoplásicos/farmacocinética , Linhagem Celular Tumoral , Citarabina/efeitos adversos , Citarabina/sangue , Citarabina/farmacocinética , Feminino , Humanos , Leucemia/tratamento farmacológico , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Ratos , Ratos Sprague-DawleyRESUMO
Acylated chitosan (Myristoyl and Octanoyl) coated paclitaxel-loaded liposomal formulation was developed with an aim to overcome the cremophor EL related toxicities. They were evaluated for drug entrapment, in vitro drug release, and cytotoxicity and cell uptake behavior using A549 cells. The 99mTc radio-labeled formulations were also evaluated in vivo in Ehrlich Ascites Tumor (EAT) bearing mice for biodistribution and tumor uptake. The mean particle size of both coated and uncoated liposomal formulations was found to be in the range of 180-200â¯nm with high drug entrapment efficiency (>90% in case of uncoated liposomes and 80⯱â¯5% in case of coated liposomes). The uncoated liposomes displayed negative zeta potential (-10.5⯱â¯4.9â¯mV) whereas coated liposomes displayed positive zeta potential in the range of +21 to +27â¯mV. Slower drug release was observed in case of liposomes coated with acylated chitosans as compared to uncoated and native chitosan coated liposomes. All liposomal formulations were found less cytotoxic than paclitaxel injection (Celtax™, Celon Labs, India). In vitro cell uptake and intracellular distribution studies confirmed the cytosolic delivery of uncoated and coated liposomes. The myristoyl chitosan coated liposomal system (LMC) exhibited improved pharmacokinetic, biodistribution and tumor uptake characteristics over other formulations. These obtained results confirmed the potential application of acylated chitosn coated liposomal delivery systems (LMC) in tumor targeting of paclitaxel and other drugs.
Assuntos
Carcinoma de Ehrlich/metabolismo , Quitosana/química , Lipossomos/química , Lipossomos/farmacocinética , Paclitaxel/química , Células A549 , Acilação , Animais , Transporte Biológico , Carcinoma de Ehrlich/patologia , Humanos , Lipossomos/metabolismo , Camundongos , Distribuição TecidualRESUMO
AIM: Paclitaxel (PTX) is an effective anticancer agent used in the therapy of a wide variety of cancers. However, the drug is difficult to formulate due to its low solubility, and therefore, it is administered under slow infusion with castor oil/ethanol solution as surfactant that causes serious side effects. This investigation investigates leutinizing hormone releasing hormone (LHRH)-tethered nanparticulate system as modality for cancer-specific delivery of PTX and therefore minimizing the adverse effects. MATERIALS & METHODS: LHRH-tethered poly(lactic-co-glycolic acid) copolymer with poly ethylene glycol side chain was synthesized, characterized and employed to formulate PTX-loaded nanoparticulate system. RESULTS & CONCLUSION: The developed nanoparticulate appears to be proficient in carrying as well as targeted delivery of PTX with improved therapeutic efficacy and better safety.
Assuntos
Antineoplásicos Fitogênicos/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Mama/efeitos dos fármacos , Portadores de Fármacos/química , Hormônio Liberador de Gonadotropina/química , Paclitaxel/administração & dosagem , Animais , Antineoplásicos Fitogênicos/farmacocinética , Antineoplásicos Fitogênicos/uso terapêutico , Mama/patologia , Neoplasias da Mama/patologia , Feminino , Humanos , Ácido Láctico/química , Células MCF-7 , Camundongos Nus , Nanopartículas/química , Paclitaxel/farmacocinética , Paclitaxel/uso terapêutico , Polietilenoglicóis/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico e Ácido PoliglicólicoRESUMO
Poly(ethylene glycol) derivatives of isoniazid with varying molecular weight of poly(ethylene glycol) were designed as antimycobacterial agents. Poly(ethylene glycol)-diacrylate of three different molecular weights (MW 258, 575, and 700) was conjugated with isoniazid by the Michael addition approach. The poly(ethylene glycol)-bis(isoniazid) conjugates thus obtained were completely characterized by FT-IR, (1)H and (13)C NMR, and ESI-MS spectroscopic techniques. Comparative MTT assay of the poly(ethylene glycol)-bis(isoniazid) conjugates showed much lower cytotoxicity than the neat isoniazid. MIC studies on Mycobaterium tuberculosis H37Rv showed potential antimycobacterial activity than the free isoniazid on a molar basis. The poly(ethylene glycol)-bis(isoniazid) conjugates were successfully radiolabeled with 99m-Technetium with more than 97% efficiency and stability to assess their in vivo fate. The (99m)Tc labeled poly(ethylene glycol)-bis(isoniazid) conjugates showed higher blood retention time in New Zealand rabbits which increased with increasing molecular weight of poly(ethylene glycol). Biodistribution studies in infection-induced murine models (BALB/c mice) showed significant retention of these conjugates at the site of infection for 72 h. The results of this study illustrate the potential utility of the PEGylated isoniazid conjugates as long circulating carriers for improved antitubercular drug therapy.
Assuntos
Antituberculosos/química , Antituberculosos/farmacologia , Isoniazida/química , Isoniazida/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Polietilenoglicóis/química , Polietilenoglicóis/farmacologia , Animais , Antituberculosos/síntese química , Antituberculosos/farmacocinética , Linhagem Celular , Desenho de Fármacos , Feminino , Humanos , Isoniazida/síntese química , Isoniazida/farmacocinética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Polietilenoglicóis/síntese química , Polietilenoglicóis/farmacocinética , Coelhos , Tuberculose/tratamento farmacológicoRESUMO
In the present study, mucoadhesive alginate microspheres of acyclovir were prepared to prolong the gastric residence time using a simple emulsification phase separation technique. The particle size of drug-loaded formulations was measured by SEM and the particle size distribution was determined using an optical microscope and mastersizer. The release profile of acyclovir from microspheres was examined in simulated gastric fluid (SGF pH 1.2). The particles were found to be discreet and spherical with the maximum particles of an average size (70.60 ± 2.44 µm). The results indicated that the mean particle size of the microspheres increased with an increase in the concentration of polymer and decreased with increase in stirring speed. The entrapment efficiency was found to be in the range of 51.42-80.46%. The concentration of the calcium chloride (% w/v) of 10% and drug-polymer ratio of 1:4 resulted in an increase in the entrapment efficiency and the extent of drug release. The optimized alginate microspheres were found to possess good mucoadhesion (66.42 ± 1.01%). The best fit model with the highest regression coefficient values (R²) was predicted by Peppas model (0.9813). In Gamma scintigraphy analysis, the section of GIT was critically analyzed and much differentiation was present at each time point after oral administration, which revealed that the optimized formulation demonstrated gastroretention in vivo for more than 4 h, which revealed that optimized formulation could be a good choice for gastroretentive systems.
Assuntos
Aciclovir/administração & dosagem , Aciclovir/química , Alginatos/administração & dosagem , Alginatos/química , Sistemas de Liberação de Medicamentos/métodos , Mucosa Gástrica/metabolismo , Aciclovir/farmacocinética , Adesividade , Animais , Disponibilidade Biológica , Cloreto de Cálcio/química , Química Farmacêutica/métodos , Preparações de Ação Retardada , Suco Gástrico/química , Suco Gástrico/metabolismo , Ácido Glucurônico/administração & dosagem , Ácido Glucurônico/química , Ácidos Hexurônicos/administração & dosagem , Ácidos Hexurônicos/química , Microesferas , Tamanho da Partícula , Polímeros/química , Coelhos , Estômago/efeitos dos fármacosRESUMO
BACKGROUND: The antitubercular drug, isoniazid (INH), has been conjugated with a bifunctional polyethylene glycol derivative (MW 575) with the objective of designing a novel drug-delivery system that has reduced toxicity compared with the neat drug, without compromising its biological activity. The polyethylene glycol-bis(INH) conjugate was synthesized in high yield and was completely characterized by infrared, NMR and mass spectroscopies. RESULTS: This conjugate was labeled with a 99mTc radionuclide with less than 95% labeling efficiency. MTT assay revealed lower cytotoxicity of the conjugate compared with INH. Blood kinetics in rabbits and biodistribution in mice compared the blood retention of the drug and its polymer conjugate and their uptake in various organs, respectively. Biodistribution and gamma-scintigraphy in infection-induced animal models showed significantly high accumulation of the polymer-drug conjugate at the site of infection and retention for a long duration. CONCLUSION: This conjugate could prove to be a good lead molecule for infection diagnosis and therapy.
Assuntos
Antituberculosos/química , Isoniazida/química , Polietilenoglicóis/química , Animais , Preparações de Ação Retardada , Isoniazida/administração & dosagem , Isoniazida/toxicidade , Camundongos , Camundongos Endogâmicos BALB C , CoelhosRESUMO
Tumor-specific gene delivery constitutes a primary challenge in nonviral mediated gene therapy. In this investigation, branched polyethylenimine (bPEI, 25 kDa) was modified by forming nanoconstructs with a natural polysaccharide, chondroitin sulfate (CS), to impart site-specific property. A library of CS-PEI (CP) nanoconstructs was fabricated by altering the content of CS and evaluated in terms of size, surface charge, morphology, pDNA loading efficiency, pDNA release assay, pDNA protection study, cytotoxicity, and transfection efficiency. In vitro transfection efficiency of CP nanoconstructs was examined in HEK293, HEK293T, HepG2, and HeLa cell lines, while their cytotoxicity was investigated in HepG2 and HeLa cells. DNase I protection assay showed that the plasmid was protected from degradation over a period of time. The CP nanoconstructs possess significantly lower toxicity and enhanced transfection efficiency compared to PEI (25 kDa) and commercial transfection reagents (i.e., superfect, fugene, and GenePORTER 2). Further, the CP nanoconstructs were also found to transfect cells in serum-containing medium. In vivo studies were carried out with pDNA loaded CP-3 nanoconstruct after intravenous (iv) injection in Ehrlich ascites tumor (EAT)-bearing mice. The outcome revealed higher concentration of CP-3 nanoconstruct in tumor mass. These findings demonstrate that CP nanoconstructs could be exploited as carriers for nanomedicine for efficient management of solid tumor.
Assuntos
Sulfatos de Condroitina/química , Expressão Gênica , Terapia Genética , Nanopartículas , Polietilenoimina/química , Animais , Carcinoma de Ehrlich/metabolismo , Linhagem Celular , DNA/metabolismo , Humanos , Camundongos , Proteínas/metabolismo , Distribuição TecidualRESUMO
Hyaluronic acid (HA)-polyethylenimine (PEI, 25 kDa) (HP) nanocomposites were fabricated for efficient targeting to solid tumors. Branched PEI was ionically blended with a natural mucopolysaccharide, HA, to partially block the positive charge and to impart site specificity to HP nanocomposites. A series of nanocomposites were prepared by varying the content of HA. HP nanocomposites were characterized by their size, morphology, zeta potential and evaluated for pDNA protection study, transfection efficiency and cytotoxicity. The competency of HP nanocomposites to relocate a plasmid encoding enhanced green fluorescent protein (pEGFP) gene was assessed in HEK293, HEK293T, and HeLa cells and found to be approximately 1-8 folds efficient compared to Superfect, Fugene, GenePORTER 2. HP nanocomposites also exhibited efficient transfection in serum-containing medium. MTT assay showed significantly improved cell viability in HEK293T, HepG2 and HeLa cells. The specificity of HP nanocomposites to target tumor was investigated in vivo by injecting pDNA-loaded HP-4 nanocomposite or PEI intravenously into mice bearing Ehrlich ascites tumor (EAT). The gamma scintigraphic studies showed a higher accumulation of HP-4 nanocomposite in the solid tumor compared to PEI. The results cumulatively advocate that HP nanocomposites could epitomize a viable alternative for site specific gene therapy.